Antibiotic Use in Myasthenia Gravis

Introduction to Antibiotic Considerations

The Centers for Disease Control and Prevention (CDC) recommends antibiotic dosing for adults and children, with specific guidelines for pertussis treatment, including azithromycin, erythromycin, and trimethoprim-sulfamethoxazole, with a strength of evidence rated as high for some recommendations 1, 2, 3
Azithromycin is recommended as the preferred antibiotic for pertussis due to its better safety profile, especially in neonates, with a dosage of 10 mg/kg/day once daily for 5 days, according to the CDC 1
Erythromycin has more drug interactions and gastrointestinal side effects than azithromycin, and is associated with infantile hypertrophic pyloric stenosis in infants under 1 month, making alternatives preferable, as reported by the CDC 1

The American Academy of Pediatrics recommends a single dose of Tdap vaccine at age 11-12 years, and a 5-dose series of DTaP vaccine at ages 2, 4, 6, 15-18 months, and 4-6 years for childhood vaccination, with a fifth dose not necessary if the fourth dose was administered after a child's fourth birthday 4, 1
Minimum intervals between doses should be maintained, with 4 weeks between doses 1-2 and 2-3, and 6 months between doses 3-4 and 4-5, according to the CDC 2
Protection from both natural infection and vaccination wanes after 5-10 years, resulting in waning immunity, as reported by the CDC 1

Pertussis should be considered in patients with acute cough illness characterized by severe or prolonged paroxysmal cough, post-tussive vomiting, whooping sound, or apnea, according to the CDC and American Thoracic Society (ATS) recommendations 5, 3
Diagnostic approach includes nasopharyngeal specimens using calcium alginate or Dacron swab for culture (definitive diagnosis) and PCR testing, as well as paired acute and convalescent sera showing fourfold increase in IgG or IgA antibodies to pertussis toxin (PT) or filamentous hemagglutinin (FHA), with a strength of evidence rated as high for culture and moderate for paired sera 4, 3

Early treatment within the first few weeks will diminish coughing paroxysms and prevent disease spread, with a moderate strength of evidence, according to the ATS guidelines 3
Antimicrobial therapy should be continued for 14 days to minimize chance of treatment failure, based on the CDC recommendations 2
Recommended antibiotic regimens for pertussis treatment include azithromycin, erythromycin, and trimethoprim-sulfamethoxazole, with specific dosing for adults and children, according to the CDC 1
Post-exposure prophylaxis is recommended for all close contacts, regardless of vaccination status, with the same antimicrobial regimens as for treatment, and is most effective when initiated within 2 weeks of exposure, according to the CDC guidelines 2, 6, 4

Patients should be isolated for 5 days from the start of antimicrobial therapy, and healthcare workers should be excluded from work until 5 days after starting appropriate therapy, based on the CDC recommendations 5
Droplet precautions should be employed for hospitalized patients, according to the CDC guidelines 5
Complications from severe coughing can occur, including pneumothorax, rib fracture, epistaxis, subconjunctival hemorrhage, subdural hematoma, hernia, rectal prolapse, urinary incontinence, and loss of consciousness/cough syncope, according to the CDC and the American College of Chest Physicians (ACCP) 1, 7

Trimethoprim-sulfamethoxazole is contraindicated in infants under 2 months, pregnant women, and nursing mothers, and has a longer treatment duration and a higher risk of adverse effects, including rash and blood dyscrasias 1
Erythromycin is associated with gastrointestinal side effects, including epigastric distress, abdominal cramps, nausea, vomiting, and diarrhea, and inhibits the cytochrome P450 enzyme system, leading to potentially serious interactions with many medications, and is also associated with infantile hypertrophic pyloric stenosis in infants under 1 month, making alternatives preferable 1
Vaccination remains the most effective prevention strategy, and pregnant women should receive Tdap between 27-36 weeks' gestation with each pregnancy, although the exact gestational age may vary depending on individual circumstances, based on the CDC recommendations 5, 1